Baidu
map

药监紧急通知:流通大放开!大公司可直接跨区布点,小药商日子不多了

2017-09-29 田边 赛柏蓝

9月27日,河南省食药监局发布紧急通知,要求下属单位就《关于鼓励法人批发企业开展设立分公司试点工作有关问题的通知》(征求意见稿)(下称意见稿),认真研究并提出修改意见,于2017年9月28日下午5点前书面反馈省局药品化妆品流通监管处。

医药流通大放开!大公司可直接布点,上万中小药商或被清扫!

9月27日,河南省食药监局发布紧急通知,要求下属单位就《关于鼓励法人批发企业开展设立分公司试点工作有关问题的通知》(征求意见稿)(下称意见稿),认真研究并提出修改意见,于2017年9月28日下午5点前书面反馈省局药品化妆品流通监管处。



▍河南鼓励大型药批,全省设分公司

河南食药监局公布了这份征求意见稿。(全文详见附件)

《意见稿》鼓励,年度纳税总额在2000万元以上(包括附加)或者年销售额20亿元以上,没有因“挂靠、走票”假药被处罚,以及没有列出诚信黑名单的批发企业,可以申请在省内设立分公司,数原则上不超过3家。

就河南药品批发企业的规模来看,能够达到这些要求的并不多。

▍中小药商的“灾难”来了

对于药批的分公司,河南食药监局允许不设仓库。

《意见稿》明确:不自设仓库的分公司,由总公司采取多仓协同的方式储存配送药品,应载明相应的的仓库地址;如果委托省内其他药品批发企业储存配送药品,载明被委托公司的仓库地址。

目前大型医药商业集团在各地扩张的障碍是,国家总体要求不增加(也就是不颁发)新的药品经营许可证,所以一些大公司到某些地方开展业务,因为没有证,比较难办。

河南此举,直接突破了这个障碍,并且可以不设仓库,就直接跨区域经营。所以对大型医药商业集团是大大的利好,对中小型医药商业公司提出了严峻挑战,要么快速做大、要么低价被兼并、要么淘汰出局。

▍大型药批,轻松扩张

对此,九州通医药集团股份有限公司副董事长刘兆年博士接受赛柏蓝访谈时表示,“虽然只有3家,但这已经是非常好的政策了,对提高行业集中度很有利,其他地区如果也能按照这个方式推广的话,对整个医药行业的发展拉动作用会很明显。”

他告诉赛柏蓝,按照现行政策,一些大公司在地市县没有网点,想深入到下面的市场去做,就需要有经营资格的公司,但是现代物流的门槛很高,而地市县市场规模本身就不大,更不可能按照现代物流标准建设。

这种情况下,常用的手法就是收购,然而对大公司来说,担心的问题不止有收购成本和当地企业的坐地起价——这家公司过往的经营可能隐藏的合规、财税等风险,都可能是更大风险的不确定性所在,而这些往往是这些异地经营的大商业们最担心的地方。

在他看来,如果大商业公司只需要设立分公司即可异地经营,意味着大商业可以快速扩张,布局网点,实现集中度大幅提高。

▍商业大兼并、大扩张,全面爆发

而在中国药品监管研究会药品流通专业委员会副主任委员、国家食药监总局专家温旭民教授看来,河南的这一次“先行”政策,也是真正落地大商业扩张、把兼并重组鼓励性文件落地的第一份地方政策。

“无论在十三五规划还是‘国十七条’中,推动产业规模化发展都是重要的一条内容,但针对性落地的政策,此次河南版文件是第一次。”他向赛柏蓝表示。

市场分析也认为,河南此举是积极落实“国办发[2017]13号”文件《关于进一步改革完善药品生产流通使用政策的若干意见》的具体措施,非常智慧,在不增加药品经营许可证数量(即不盲目增加医药流通企业数量)的前提下,突破了大型药品流通企业异地经营的障碍,从而使行业中长期存在的“优不胜、劣不汰”的现象得以扭转,使优质企业、大型医药流通集团得到快速扩张,使一些靠挂靠、走票的投机性的中小型公司被淘汰出局。

附:河南食药监局《关于鼓励法人批发企业开展设立分公司试点工作有关问题的通知》

各省辖市、省直管县(市)食品药品监督管理局,郑州航空港经济综合实验区食品药品监督管理局:

为贯彻落实《关于改革完善药品生产流通使用政策推动医药产业健康发展的意见》(豫食药监药化监﹝2017﹞131号),推动药品流通企业转型升级,鼓励法人批发企业开展设立分公司试点工作,省局经研究,现将有关事项通知如下:

一、申办条件

除满足《药品经营许可证管理办法》相关要求外,鼓励年度纳税总额在2000万元以上(包括附加)或者年销售额20亿元以上,且三年来未受到因“挂靠、走票”及经营假药而受到食品药品监管部门行政处罚、未被政府部门列入诚信企业“黑榜”名单的单体法人药品批发企业,申请在省辖市区设立数量原则上不超过3家的分公司。

二、分公司《药品经营许可证》的管理

(一)申领分公司《药品经营许可证》的程序

1.申请验收发证

除提交《药品经营许可证管理办法》规定的相关材料外,申办企业尚需提交:

(1)辖区税务部门出具的上年度纳税总额在2000万元以上(包括附加)或者年销售额20亿元以上的证明材料。

(2)通过《国家企业信用信息公示系统》和辖区食品药品监督部门,分别打印、出具未被政府部门列入诚信企业“黑榜”名单的信息和三年来未受到因“挂靠、走票”及经营假药而受到食品药品监管部门行政处罚的证明材料。

(3)申办企业对申请材料真实性的自我保证声明及对申请材料作出的如有虚假承担法律责任的承诺。

2.验收发证

依据国家局《开办药品批发企业验收实施标准(试行)》组织验收,分公司应具有与其经营品种和规模相适应的符合GSP要求的常温库、阴凉库、冷库。分公司可自设仓库,也可由其总公司整合系统内药品仓储和运输资源,采取多仓协同的方式储存配送药品,或者委托省内其他药品批发企业储存配送药品。验收不自设仓库的分公司时,《开办药品批发企业验收实施标准(试行)》中的相关验收内容应为合理缺陷项目。符合条件的,发给《药品经营许可证》;不符合条件的,书面通知申办人并说明理由,同时告知申办人享有依法申请行政复议或提起行政诉讼的权利。

3. 分公司《药品经营许可证》应当载明企业名称、法定代表人或企业负责人姓名、经营方式、经营范围、注册地址、仓库地址、《药品经营许可证》证号、流水号、发证机关、发证日期、有效期限等项目。

(1)不自设仓库的分公司,如果由总公司采取多仓协同的方式储存配送药品,其《药品经营许可证》应当载明相应的的仓库地址。

(2)不自设仓库的分公司,如果委托省内其他药品批发企业储存配送药品,其《药品经营许可证》应当载明被委托公司的仓库地址。

(二)分公司《药品经营许可证》的变更与换发

1.分公司《药品经营许可证》的变更按照《药品经营许可证管理办法》的相关规定执行。

2.分公司《药品经营许可证》的有效期限与其总公司的《药品经营许可证》的有效期限相同。分公司《药品经营许可证》换证按照《药品经营许可证管理办法》等法律法规的相关规定执行。

(三)分公司经营范围不得超出其总公司经营范围且不含特殊管理药品。

三、《药品经营质量管理规范》认证管理

(一)分公司药品经营质量管理规范认证管理按照《药品经营质量管理规范认证管理办法》执行。初次认证检查时,《药品经营质量管理规范现场检查指导原则》中涉及经营活动的动态条款内容为合理缺陷项目。

(二)分公司《药品经营质量管理规范认证证书》的有效期限与其总公司的《药品经营质量管理规范认证证书》的有效期限相同。

(三)对不自设仓库的分公司,《药品经营质量管理规范现场检查指导原则》中的相关内容为合理缺陷项目。

四、核发证书

对分公司核发证书,采取将药品经营行政许可与药品经营质量管理规范认证两次检查“合二为一”的方式,按照一次申请、合并检查,符合要求的,同时发放《药品经营许可证》、《药品经营质量管理规范认证证书》。

五、日常监督管理

分公司的日常监督管理按照“属地管理”执行。注册地址、仓库地址不在同一辖区的分公司,其仓库由所在地食品药品监管部门进行日常监管工作。

案件跨区域或有管辖争议的,由省食品药品监督管理局依法指定管辖。

附件:

1. 药品经营许可证(非法人、批发)核发

2. 药品经营许可证(非法人、批发)变更

3. 药品经营许可证(非法人、批发)换证

4. 药品批发企业分公司药品经营质量管理规范认证和重新认证办事指南

5. 药品批发企业分公司《药品经营质量管理规范认证证书》变更

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987805, encodeId=83bc198e80584, content=<a href='/topic/show?id=81dde7032db' target=_blank style='color:#2F92EE;'>#紧急通知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77032, encryptionId=81dde7032db, topicName=紧急通知)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon May 21 09:38:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523213, encodeId=c9d515232131d, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535050, encodeId=84b31535050a7, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248743, encodeId=d94f248e43e2, content=医药改革迟早要来, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/27/c3e43bd6e32a923e5039c647133f8782.jpg, createdBy=b0b92146849, createdName=小鹿啊, createdTime=Fri Sep 29 08:43:35 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248701, encodeId=df4e248e0189, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Sep 29 07:02:51 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248692, encodeId=80252486924a, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Sep 29 06:59:05 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248668, encodeId=bf542486682d, content=谢谢分享知识学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Fri Sep 29 06:00:03 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248656, encodeId=70eb248656db, content=两票加一票, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Sep 29 02:47:58 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987805, encodeId=83bc198e80584, content=<a href='/topic/show?id=81dde7032db' target=_blank style='color:#2F92EE;'>#紧急通知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77032, encryptionId=81dde7032db, topicName=紧急通知)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon May 21 09:38:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523213, encodeId=c9d515232131d, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535050, encodeId=84b31535050a7, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248743, encodeId=d94f248e43e2, content=医药改革迟早要来, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/27/c3e43bd6e32a923e5039c647133f8782.jpg, createdBy=b0b92146849, createdName=小鹿啊, createdTime=Fri Sep 29 08:43:35 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248701, encodeId=df4e248e0189, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Sep 29 07:02:51 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248692, encodeId=80252486924a, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Sep 29 06:59:05 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248668, encodeId=bf542486682d, content=谢谢分享知识学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Fri Sep 29 06:00:03 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248656, encodeId=70eb248656db, content=两票加一票, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Sep 29 02:47:58 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987805, encodeId=83bc198e80584, content=<a href='/topic/show?id=81dde7032db' target=_blank style='color:#2F92EE;'>#紧急通知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77032, encryptionId=81dde7032db, topicName=紧急通知)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon May 21 09:38:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523213, encodeId=c9d515232131d, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535050, encodeId=84b31535050a7, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248743, encodeId=d94f248e43e2, content=医药改革迟早要来, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/27/c3e43bd6e32a923e5039c647133f8782.jpg, createdBy=b0b92146849, createdName=小鹿啊, createdTime=Fri Sep 29 08:43:35 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248701, encodeId=df4e248e0189, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Sep 29 07:02:51 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248692, encodeId=80252486924a, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Sep 29 06:59:05 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248668, encodeId=bf542486682d, content=谢谢分享知识学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Fri Sep 29 06:00:03 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248656, encodeId=70eb248656db, content=两票加一票, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Sep 29 02:47:58 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987805, encodeId=83bc198e80584, content=<a href='/topic/show?id=81dde7032db' target=_blank style='color:#2F92EE;'>#紧急通知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77032, encryptionId=81dde7032db, topicName=紧急通知)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon May 21 09:38:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523213, encodeId=c9d515232131d, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535050, encodeId=84b31535050a7, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248743, encodeId=d94f248e43e2, content=医药改革迟早要来, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/27/c3e43bd6e32a923e5039c647133f8782.jpg, createdBy=b0b92146849, createdName=小鹿啊, createdTime=Fri Sep 29 08:43:35 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248701, encodeId=df4e248e0189, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Sep 29 07:02:51 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248692, encodeId=80252486924a, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Sep 29 06:59:05 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248668, encodeId=bf542486682d, content=谢谢分享知识学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Fri Sep 29 06:00:03 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248656, encodeId=70eb248656db, content=两票加一票, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Sep 29 02:47:58 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 小鹿啊

    医药改革迟早要来

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1987805, encodeId=83bc198e80584, content=<a href='/topic/show?id=81dde7032db' target=_blank style='color:#2F92EE;'>#紧急通知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77032, encryptionId=81dde7032db, topicName=紧急通知)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon May 21 09:38:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523213, encodeId=c9d515232131d, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535050, encodeId=84b31535050a7, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248743, encodeId=d94f248e43e2, content=医药改革迟早要来, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/27/c3e43bd6e32a923e5039c647133f8782.jpg, createdBy=b0b92146849, createdName=小鹿啊, createdTime=Fri Sep 29 08:43:35 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248701, encodeId=df4e248e0189, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Sep 29 07:02:51 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248692, encodeId=80252486924a, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Sep 29 06:59:05 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248668, encodeId=bf542486682d, content=谢谢分享知识学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Fri Sep 29 06:00:03 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248656, encodeId=70eb248656db, content=两票加一票, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Sep 29 02:47:58 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 明月清辉

    谢谢分享.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1987805, encodeId=83bc198e80584, content=<a href='/topic/show?id=81dde7032db' target=_blank style='color:#2F92EE;'>#紧急通知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77032, encryptionId=81dde7032db, topicName=紧急通知)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon May 21 09:38:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523213, encodeId=c9d515232131d, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535050, encodeId=84b31535050a7, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248743, encodeId=d94f248e43e2, content=医药改革迟早要来, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/27/c3e43bd6e32a923e5039c647133f8782.jpg, createdBy=b0b92146849, createdName=小鹿啊, createdTime=Fri Sep 29 08:43:35 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248701, encodeId=df4e248e0189, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Sep 29 07:02:51 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248692, encodeId=80252486924a, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Sep 29 06:59:05 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248668, encodeId=bf542486682d, content=谢谢分享知识学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Fri Sep 29 06:00:03 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248656, encodeId=70eb248656db, content=两票加一票, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Sep 29 02:47:58 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 飛歌

    厉害了我的哥

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1987805, encodeId=83bc198e80584, content=<a href='/topic/show?id=81dde7032db' target=_blank style='color:#2F92EE;'>#紧急通知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77032, encryptionId=81dde7032db, topicName=紧急通知)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon May 21 09:38:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523213, encodeId=c9d515232131d, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535050, encodeId=84b31535050a7, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248743, encodeId=d94f248e43e2, content=医药改革迟早要来, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/27/c3e43bd6e32a923e5039c647133f8782.jpg, createdBy=b0b92146849, createdName=小鹿啊, createdTime=Fri Sep 29 08:43:35 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248701, encodeId=df4e248e0189, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Sep 29 07:02:51 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248692, encodeId=80252486924a, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Sep 29 06:59:05 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248668, encodeId=bf542486682d, content=谢谢分享知识学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Fri Sep 29 06:00:03 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248656, encodeId=70eb248656db, content=两票加一票, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Sep 29 02:47:58 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 1e1a50a1m36(暂无匿称)

    谢谢分享知识学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1987805, encodeId=83bc198e80584, content=<a href='/topic/show?id=81dde7032db' target=_blank style='color:#2F92EE;'>#紧急通知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77032, encryptionId=81dde7032db, topicName=紧急通知)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon May 21 09:38:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523213, encodeId=c9d515232131d, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535050, encodeId=84b31535050a7, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Sep 30 15:38:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248743, encodeId=d94f248e43e2, content=医药改革迟早要来, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/27/c3e43bd6e32a923e5039c647133f8782.jpg, createdBy=b0b92146849, createdName=小鹿啊, createdTime=Fri Sep 29 08:43:35 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248701, encodeId=df4e248e0189, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Sep 29 07:02:51 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248692, encodeId=80252486924a, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Sep 29 06:59:05 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248668, encodeId=bf542486682d, content=谢谢分享知识学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Fri Sep 29 06:00:03 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248656, encodeId=70eb248656db, content=两票加一票, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Sep 29 02:47:58 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 lou.minghong

    两票加一票

    0

相关资讯

两票制大动作!国务院医改办、国税总局要联手查票

两票制最新消息:国务院医改办与国税总局联手查票、两票制文件正在制定......

两票制来了,基层医疗市场谁会哭谁会笑?

国务院推行“两票制”以来,全国各省市根据自身情况纷纷实施和执行了两票制,从政策发布和落地的速度可以预见,医药流通行业将很快迎来“大洗牌”。

Baidu
map
Baidu
map
Baidu
map